0000000000653713

AUTHOR

Roberto Ferrara

showing 2 related works from this author

Myeloid cell heterogeneity in lung cancer: implication for immunotherapy

2020

Lung is a specialized tissue where metastases from primary lung tumors takeoff and those originating from extra-pulmonary sites land. One commonality characterizing these processes is the supportive role exerted by myeloid cells, particularly neutrophils, whose recruitment is facilitated in this tissue microenvironment. Indeed, neutrophils have important part in the pathophysiology of this organ and the key mechanisms regulating neutrophil expansion and recruitment during infection can be co-opted by tumor cells to promote growth and metastasis. Although neutrophils dominate the myeloid landscape of lung cancer other populations including macrophages, dendritic cells, mast cells, basophils …

Cancer ResearchLung NeoplasmsMyeloidmedicine.medical_treatmentImmunologyCellGene ExpressionContext (language use)ReviewSettore MED/08 - Anatomia PatologicaBiologyMetastasis03 medical and health sciences0302 clinical medicineImmune systemBiomarkers TumormedicineAnimalsHumansImmunology and AllergyMolecular Targeted TherapyDNA-based trapsLung cancerLung cancer · Myeloid cells · DNA-based traps · ImmunotherapyLungDisease ManagementImmunotherapymedicine.diseaseImmunohistochemistrymedicine.anatomical_structureOncologyMyeloid cellsCancer researchDisease SusceptibilityImmunotherapyLung cancerBiomarkers030215 immunologyCancer Immunology, Immunotherapy
researchProduct

The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-S…

2022

The development of innovative technologies and the advances in the genetics and genomics, have offered new opportunities for personalized treatment in oncology. Although the selection of the patient based on the molecular characteristics of the neoplasm has the potential to revolutionize the therapeutic scenario of oncology, this approach is extremely challenging. The access, homogeneity, and economic sustainability of the required genomic tests should be warranted in the clinical practice, as well as the specific scientific and clinical expertise for the choice of medical therapies. All these elements make essential the collaboration of different specialists within the Molecular Tumor Boar…

Societies ScientificMolecularScientificPrecision oncologyHematologyGenomicsMolecular profiling; Molecular tumor board; Mutational oncology; Precision oncologyMolecular tumor boardSettore MED/03 - GENETICA MEDICAMedical OncologyMolecular profilingMutational oncologyOncologyItalyNeoplasmsMolecular profiling; Molecular tumor board; Mutational oncology; Precision oncology; Genomics; Humans; Italy; Medical Oncology; Neoplasms; Societies ScientificGenomicNeoplasmHumansSocietiesHuman
researchProduct